<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521950</url>
  </required_header>
  <id_info>
    <org_study_id>945-07-606</org_study_id>
    <secondary_id>CMO 2006/129</secondary_id>
    <secondary_id>ABR NL13171.091.06</secondary_id>
    <nct_id>NCT00521950</nct_id>
  </id_info>
  <brief_title>Cost-effectiveness of TPMT Pharmacogenetics</brief_title>
  <acronym>TOPIC</acronym>
  <official_title>Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether thiopurine S-methyltransferase (TPMT)
      genotyping prior to thiopurine use is cost-effective in patients with inflammatory bowel
      disease (IBD) in need of immune suppression.

      The study is designed to test the hypothesis that optimization of initial thiopurine dose
      based on pre-treatment TPMT genotyping will maximize treatment efficacy and minimize adverse
      drug reactions (ADRs) resulting in reduced costs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunosuppressives, e.g. azathioprine (AZA) and 6-mercaptopurine (6-MP), are important in
      induction of remission and long term treatment of (ulcerative) colitis and Crohn's disease
      when treatment with 5-aminosalicylates and corticosteroids fails. ADRs to immunosuppressive
      treatment, including myelosuppression and hepatotoxicity, are frequently (15-30%) observed.
      Genetic variation in the TPMT gene results in 10-11% of the general population in reduced and
      in 0.3-0.6% to negligible TPMT enzyme activity. In IBD patients, this genetic variation
      predicts 25-40% of the haematological ADRs necessitating tempering of thiopurine dose or
      discontinuation of treatment.

      Pharmacogenetics aims at providing optimized drug treatment to patients by maximizing
      efficacy and minimizing adverse drug reactions (ADRs) based on genetic testing. Despite the
      proven value of pharmacogenetics in clinical practice, its use in medical care is still
      limited.

      The best-established example of a pharmacogenetic test is genotyping of thiopurine
      S-methyltransferase (TPMT) in the treatment of patients with immunosuppressive thiopurines.
      Nonetheless, it is not used on a large scale in clinical practice so far, which might be due
      to: insufficient information transfer from research to clinic; lack of cost-effectiveness
      analyses (CEAs); lack of availability of (or access to) fast and/or cheap genotyping; or lack
      of test reimbursement by health insurance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haematological adverse drug reactions</measure>
    <time_frame>0-5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-haematological Adverse Drug Reactions</measure>
    <time_frame>0- 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome (disease activity)</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>0 to 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TPMT enzym activity</measure>
    <time_frame>at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Drug Monitoring of TPMT Metabolites</measure>
    <time_frame>week 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-efficacy</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">853</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Intervention, TPMT genotyping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-treatment TPMT genotyping to optimize initial thiopurine treatment dose. Intervention is based on the genotype.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard thiopurine treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>TPMT genotyping; Drug: azathioprine or 6-mercaptopurine</intervention_name>
    <description>Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT*2, *3A, *3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.
Patients are advised an initial treatment dose based on the enzyme activity:
Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);
Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;
Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;</description>
    <arm_group_label>Intervention, TPMT genotyping</arm_group_label>
    <other_name>Imuran</other_name>
    <other_name>Puri-Nethol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azathioprine (AZA) or 6-mercaptopurine (6-MP)</intervention_name>
    <description>Patients will be advised a standard initial treatment dose:
AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);</description>
    <arm_group_label>control</arm_group_label>
    <other_name>Imuran</other_name>
    <other_name>Puri-Nethol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Diagnosis of a form of IBD

          -  Indication for azathioprine/6-MP treatment

          -  Patient giving (written) informed consent

        Exclusion Criteria:

          -  Previous treatment with azathioprine/6-MP

          -  Co-prescription of allopurinol (this treatment blocks xanthine oxidase, an enzyme
             important for thiopurine metabolism)

          -  Baseline leukocyte count less then 3x10^9 per litre

          -  Reduced liver function at baseline

          -  Reduced renal function at baseline

          -  Known TPMT phenotype (enzyme activity / Therapeutic Drug Monitoring) or genotype

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Franke, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Scheffer, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corine J van Marrewijk, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk J de Jong, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marieke JH Coenen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henk-Jan Guchelaar, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden UMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luc Derijks, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Maxima MC Veldhoven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olaf Klungel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andr√© Verbeek, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sita Vermeulen, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernhoven Hospital</name>
      <address>
        <city>Oss</city>
        <zip>5342 BT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernhoven Hospital</name>
      <address>
        <city>Veghel</city>
        <zip>5461 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.humangenetics.nl/</url>
    <description>Department of Human Genetics Nijmegen</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2007</study_first_posted>
  <last_update_submitted>March 27, 2014</last_update_submitted>
  <last_update_submitted_qc>March 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>Marieke Coenen</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Cost Effectiveness</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Crohn Disease</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Randomized Controlled Trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

